December 20, 2023The Medicine ForumOpen Access

Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study

View Full Paper

Ask AI

Bookmark

Abstract

Long-term outcomes from the phase 2 SMART trial demonstrate encouraging OS and limited severe toxicity. Additional prospective evaluation of this novel strategy is warranted.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chuong et al. (2023) studied this question.

synapsesocial.com/papers/69d6d8aefca0359822aa8b5d https://doi.org/10.1016/j.radonc.2023.110064

View Full Paper

Ask AI

Bookmark

Abstract

Long-term outcomes from the phase 2 SMART trial demonstrate encouraging OS and limited severe toxicity. Additional prospective evaluation of this novel strategy is warranted.

Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study

Abstract

Discussion

Cite This Study

Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading